Future management of schizophrenia: An acute psychotic episode treated by olanzapine (case report);Nouvelles strategies therapeutiques dans la schizophrenie: A propos d'une decompensation aigue traitee par olanzapine

Encephale

Volumn 26, Issue 2, 2000, Pages 89-91

  Portier, A ^a   Antonetti, J F ^b  

^a CENTRE HOSPITALIER VICTOR DUPOUY   (France)

^b Psychiatre   (France)

Author keywords

Antipsychotic; Olanzapine; Schizophrenia

Indexed keywords

OLANZAPINE; BENZODIAZEPINE DERIVATIVE; DRUG DERIVATIVE; NEUROLEPTIC AGENT; PIRENZEPINE;

ADULT; ARTICLE; CASE REPORT; FOLLOW UP; HUMAN; MALE; PSYCHOSIS; SCHIZOPHRENIA; ACUTE DISEASE; HEBEPHRENIA; PSYCHOLOGICAL RATING SCALE; SOCIAL ADAPTATION;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FOLLOW-UP STUDIES; HUMANS; MALE; PIRENZEPINE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA, DISORGANIZED; SOCIAL ADJUSTMENT;

EID: 0034078911     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. BLONDIAUX I, ALAGILLE M, GINESTET D. Adhésion aux traitements biologiques en psychiatrie. EMC Psychiatrie, 37-860-A50, 1994, 3p.
2. CHABANNES JP, ANTONIOL B, BOTTAI T et al. Place des anti-psychotiques dans les états aigus de psychose. Nervure 1999 ; XII (6) : 62-8.
3. DALERY J, SAOUD M. Les neuroleptiques : nouvelles perspectives. In : Dalery J, d'Amato T (eds), « La schizophrénie, recherches actuelles et perspectives », Masson 1999 : 171-93.
4. FLEISCHHACKER WW, HUMMER M. Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes. Drugs 1997 ; 53 (6) : 915-929.
5. HAMILTON SH, REVICKI DA, GENDUSO LA, BEASLEY CM. Olanzapine versus placebo and haloperidol : quality of life and efficacy results of the north american double-blind trial. Neuropsychopharmacology 1998 ; 18 : 41-9.
6. LIEBERMAN JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia : a rationale and hypothesis. J Clin Psychiatry 1996 ; 57 (Suppl 11) : 68-71.
7. MELTZER HY, MCGURK SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin 1999 ; 25 (2) : 233-55.
8. OLIE JP, SPADONE C, SARFATI Y. Thérapeutiques biologiques : état actuel des traitements neuroleptiques et voies de recherches. In : Scotto JC, Bougerol T (eds), « Les schizophrénies, aspects actuels », Flammarion Médecine-Sciences 1997 : 197-216.
9. PURDON SE, JONES BD, STIP E et al. Neuropsychologicalchange in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry 2000 ; 57 (3) : 249-58.
10. SANGER TM, LIEBERMAN JA, TOHEN M et al. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999 ; 156 : 79-87.
11. SARFATI Y, OLIVER V, BOUHASSIRA M. Utilisation des nouveaux antipsychotiques dans le traitement de la schizophrénie. Une enquête européenne. L'Encephale 1999 ; XXV : 658-66.
12. TOLLEFSON GD, BEASLEY CM, Tran PV et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders : results of an international collaborative trial Am J Psychiatry 1997 ; 154 : 457-465.
13. TRAN PV, DELLVA MA, TOLLEFSON GD et al. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997 ; 58 : 205-11.
14. TRAN PV, DELLVA MA, TOLLEFSON GD et al. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry 1998 ; 172 : 499-505.
15. VANELLE JM. Traitement chimiothérapique des schizophrénies. EMC Psychiatrie 37-295-A10, 2000, 11p.